ADC Therapeutics' Lonca, or loncastuximab tesirine, was granted priority review status by the FDA as a treatment for relapsed or refractory diffuse large B-cell lymphoma. The designation was based on results from a trial that linked the drug to a 48% overall response rate in previously treated DLBCL patients who had undergone an average of three systemic therapies.